DE2154279A1 - Medikamente für das fibrinolytische System - Google Patents

Medikamente für das fibrinolytische System

Info

Publication number
DE2154279A1
DE2154279A1 DE19712154279 DE2154279A DE2154279A1 DE 2154279 A1 DE2154279 A1 DE 2154279A1 DE 19712154279 DE19712154279 DE 19712154279 DE 2154279 A DE2154279 A DE 2154279A DE 2154279 A1 DE2154279 A1 DE 2154279A1
Authority
DE
Germany
Prior art keywords
fibrinolytic
preparations
activity
fibrinolytic system
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19712154279
Other languages
German (de)
English (en)
Inventor
A Butti
M Mantovani
G Prino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crinos Industria Farmacobiologica SpA
Original Assignee
Crinos Industria Farmacobiologica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinos Industria Farmacobiologica SpA filed Critical Crinos Industria Farmacobiologica SpA
Publication of DE2154279A1 publication Critical patent/DE2154279A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19712154279 1970-11-03 1971-10-30 Medikamente für das fibrinolytische System Pending DE2154279A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT3130970 1970-11-03

Publications (1)

Publication Number Publication Date
DE2154279A1 true DE2154279A1 (de) 1972-05-25

Family

ID=11233433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19712154279 Pending DE2154279A1 (de) 1970-11-03 1971-10-30 Medikamente für das fibrinolytische System

Country Status (4)

Country Link
US (1) US3829567A (enExample)
DE (1) DE2154279A1 (enExample)
FR (1) FR2112422B1 (enExample)
GB (1) GB1367655A (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558010A (en) * 1980-04-03 1985-12-10 Abbott Laboratories Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom
JPS59219235A (ja) * 1983-05-30 1984-12-10 Mitsui Toatsu Chem Inc 消化性潰瘍用剤
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US5182269A (en) * 1987-09-23 1993-01-26 Crinos Industria Farmacobiologica Spa Composition for topical use having hair stimulating, anti-dandruff and anti-seborrhoic activity
IT1223322B (it) * 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
IT1231509B (it) * 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
EP1147777A1 (en) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
US8771663B2 (en) * 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1325962A1 (en) * 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
KR20070121001A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
CN107007617A (zh) 2010-11-12 2017-08-04 真蒂奥姆责任有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
WO2013190582A1 (en) 2012-06-22 2013-12-27 Gentium S.P.A. Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CA3071544A1 (en) 2017-08-03 2019-02-07 Jazz Pharmaceuticals Ireland Limited Formulations comprising a nucleic acid in a high concentration
AU2019252790A1 (en) 2018-04-12 2020-10-15 Jazz Pharmaceuticals, Inc. Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
US20230086833A1 (en) 2020-04-17 2023-03-23 Jazz Pharmaceuticals Ireland Limited Defibrotide treatment for the prevention of organ rejection and injury
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Also Published As

Publication number Publication date
FR2112422A1 (enExample) 1972-06-16
FR2112422B1 (enExample) 1975-10-10
US3829567A (en) 1974-08-13
GB1367655A (en) 1974-09-18

Similar Documents

Publication Publication Date Title
DE2154279A1 (de) Medikamente für das fibrinolytische System
DE68907124T3 (de) Verfahren zum Stabilisieren von menschlichen Albuminlösungen und so erhaltene Lösung.
AT392081B (de) Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen
DE69033560T2 (de) Arzneimittel für insulinresistente diabetiker
DE69333378T2 (de) Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
DE69634751T2 (de) MODIFIZIERTE METHIONINASE, DEREN VERWENDUNG, REKOMBINANTE WIRTsZELLEN DIE GROSSE MENGEN VON METHIONINASE PRODUZIEREN UND VERFAHREN ZUR AUFREINIGUNG VON METHIONINASE
DE3433329C2 (enExample)
CH684310A5 (de) Substituierte Adeninderivate.
DE2850247A1 (de) Loesungen von glucosepolymergemischen mit niedrigem molekulargewicht und hohem kaloriengehalt, geeignet zur intravenoesen verabreichung
EP0322659B1 (de) Verwendung von polysulfatierten Heparinen
DE2635065C2 (de) Verfahren zur halbkontinuierlichen Behandlung von Gesamtblut zur Herstellung von biologisch aktiven hämatopoetischen Chalonextrakten
DE2051745A1 (de) Von Nucleinsäuren stammende Arznei mittel und Verfahren zu ihrer Herstellung
DE3019847C2 (de) Verfahren zur Herstellung von Humaninterferon
EP0602686B1 (de) Lektinkonzentrate aus Mistelextrakten und entsprechende standardisierte, stabilisierte Mistellektinpräparate, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel und deren Verwendung zur Erhöhung der natürlichen Immunresistenz und/oder in der Tumor-Therapie
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
Wen Micropuncture studies of glucose transport in the dog: mechanism of renal glycosuria
DE60216292T2 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
DE3879575T2 (de) Alpha-Carotin zur Wachstumshemmung von Krebszellen.
DE2723451A1 (de) Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln
EP2393504B1 (de) Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren
DE69230931T2 (de) Gefallene zellen und ihre verwendung in arzneimitteln
DE69527205T2 (de) Arzneimittel gegen endotoxinschock und dadurch ausgelöstes multiples organversagen
DE60219770T2 (de) Krebsmittel
DE60036790T2 (de) Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion
DE69534016T2 (de) Verwendung von thrombomodulin gegen lebererkrankungen